Pay in 4 interest-free payments of $6.92 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Ueno M, Miura S, Ohama R, et al
doi: 10.1371/journal.ppat.1000874 282 Schubert-UnkmeirA.SokolovaO.PanznerU.EigenthalerM.FroschM
doi:10.1007/s00204-012-0924-1 Hinson JA, Roberts DW, James LP (2010) Mechanisms of acetaminophen-induced liver necrosis
Tirzepatide and endometriosis: the dual-agonist advantage Tirzepatide offers something semaglutide does not: dual agonism of both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors
Primary candidates for GLP-1 therapy include: Patients with type 2 diabetes and inadequate glycemic control despite metformin therapy Individuals with type 2 diabetes and established atherosclerotic cardiovascular disease Patients with type 2 diabetes and multiple cardiovascular risk factors (hypertension, dyslipidemia, obesity) Adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with weight-related comorbidities Patients with metabolic syndrome who have not achieved adequate risk factor control with lifestyle modification For patients with dyslipidemia, GLP-1 agents may be particularly valuable when combined with statin therapy in those who have not reached LDL-C goals or who have persistent hypertriglyceridemia despite statin treatment
US$ 24.84
US$ 26.47
US$ 21.20
US$ 24.90
